BioNTech SE (NASDAQ:BNTX) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in shares of BioNTech SE (NASDAQ:BNTX) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,513 shares of the company’s stock after selling 418 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $400,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Fred Alger Management LLC purchased a new position in shares of BioNTech during the 3rd quarter valued at approximately $59,485,000. Baillie Gifford & Co. raised its holdings in BioNTech by 0.4% in the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after acquiring an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after acquiring an additional 7,340 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after acquiring an additional 74,119 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX opened at $111.89 on Thursday. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $26.82 billion, a PE ratio of -53.28 and a beta of 0.17. The firm has a 50-day moving average price of $117.18 and a 200 day moving average price of $108.97.

Wall Street Analysts Forecast Growth

BNTX has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 26th. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a report on Monday, December 2nd. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $150.00 price target on shares of BioNTech in a research report on Monday, November 18th. Finally, Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.